Kairos Pharma (KAPA) Non-Current Assets (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Non-Current Assets came in at $1.2 million in Q4 2025, down 27.89% YoY from $1.6 million in Q4 2024, and down 37.13% on a QoQ basis from $1.8 million in Q2 2025.
Kairos Pharma (KAPA) Non-Current Assets (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Non-Current Assets data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Non-Current Assets fell 27.89% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 27.89% YoY) and the FY2025 annual result came in at $1.2 million, down 27.89% from the prior year.
- Non-Current Assets declined to $1.2 million in Q4 2025, from $1.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.9 million in Q1 2025 to a low of $262000.0 in Q3 2024.
- A 3-year average of $1.3 million and a median of $1.4 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets surged 85.07% — and 2025, when it retreated 27.89%.
- Tracing KAPA's Non-Current Assets over 3 years: stood at $864000.0 in 2023, then surged by 85.07% to $1.6 million in 2024, then declined by 27.89% to $1.2 million in 2025.
- The last three Non-Current Assets figures came in at $1.2 million (Q4 2025), $1.8 million (Q2 2025), and $1.9 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Kairos Pharma | 5.50 Mn | 168,380.07 | - | 1.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Sep 30, 2024 | 262,000.00 |
| Dec 31, 2023 | 864,000.00 |